Publication | Closed Access

Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

Interferon α2BHepatologyHepatitis CHepatitis C VirusViral HepatitisHepatitis BHepatitisAntiviral TherapyChronic Viral InfectionAntiviral DrugMedicineChronic Infection